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Thyroid dysfunction can predict response to immunotherapy with
interleukin-2 and interferon-2a
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Sunmnary Thyroid dysfunction is a well-recognised side-effect of treatment with interleukin-2 (IL2). We
assessed the correlation between the development of abnormal thyroid function and tumour response in 13
patients receiving IL2 and interferon-2a (IFN2a) for advanced malignancy.
Seven patients had normal thyroid function during treatment, and all of these patients have since died of
progressive disease. Ofsix patients who did develop thyroid dysfunction during treatment, one patient has died
of progressive disease. However, statistically we were unable to confirm a definite correlation between the
development of thyroid dysfunction and survival in this small group of patients.
Over the past 14 years Interleukin-2 (IL-2) has been exten-
sively investigated as an anti-tumour agent. Its main role at
present is in the treatment of metastatic renal cell carcinoma
and malignant melanoma, where IL-2 has been used alone
and also in combination with other agents such as interferon,
lymphokine-activated killer (LAK) cells or tumour-infiltrat-
ing lymphocytes (TIL). Documented response rates in renal
cell carcinoma and malignant melanoma in patients treated
with IL-2, or with combinations of IL-2 and one of the
above agents, range from 20-40% (Rosenberg et al., 1987;
Rosenberg et al., 1989). Treatment with IL-2 is associated
with a well-documented range of side-effects (Lotze et al.,
1986b; Parkinson, 1988; Lotze et al., 1986a). Abnormalities
of thyroid function in association with IL-2 treatment were
first noted by Atkins et al. in 1988. The reason for this
association is not clear, but of particular interest is the
suggestion that the development of thyroid dysfunction may
be a marker of response to IL-2 treatment.
This report assesses the correlation between thyroid func-
tion and tumour response in a group of patients treated with
IL-2 and Interferon-2a (IFN-2a) for disseminated malignant
disease.
Methods
Patients were treated as part of an open non-randomised
study using a combination of IL-2 and IFN-2a. Patients
eligible for this study had histologically confirmed, progres-
sive, metastatic or recurrent malignant melanoma or renal
cell carcinoma unsuitable for further surgery. All patients
with renal cell carcinoma had previously undergone nephrec-
tomy.
Each patient gave written informed consent to entry into
the study and the study protocol was approved by the Insti-
tutional Review Board and Ethics Committee of the hospital.
Treatment protocol
The treatment protocol was based on a 14 day treatment
cycle (IL-2 and IFN-2a were provided by Roche Ireland Ltd,
Bray, Co Wicklow). IL-2 at 3 MU m2 day-' was given by
continuous intravenous infusion over days 1-4 (96 h). IFN-
2a 6 MU m-2 day' was given as a subcutaneous bolus injec-
tion on days 1 and 4. There was then a 10 day rest period,
and the cycle began again on the 15th day. IL-2 was admini-
stered via central venous access line and regulated by a
continuous infusion pump.
Tumour measurement was performed after the second and
fourth treatment cycles. After four cycles patients with pro-
gressive disease were withdrawn from the study. Patients with
stable disease or better continued for a further nine cycles to
a total of 13 cycles. Tumour assessment was then performed
at monthly intervals and patients with documented progres-
sive disease were withdrawn from the study at the time of
diagnosis. After 13 cycles treatment ceased in patients with
progressive disease or stable disease. Patients with complete
or partial response continued treatment for a further 13
cycles up to a total of 26 cycles.
Thyroidfunction
Serum thyroxin (T4) and thyrotropin (TSH) were measured
by radioimmunoassay. Serum levels of thyroid antibodies
(anti-thyroglobulin and anti-thyroid microsomal antibody)
were measured by passive haemagglutination with commer-
cial kits (Wellcome Ltd, Airton Road, Tallaght, Dublin 24).
Anti-microsomal antibody titre above 1:100 and anti-thyro-
globulin antibody titre above 1:10 were considered elevated.
Thyroid function tests were performed on all patients prior
to entry into the study and on days 1 and 4 of each treat-
ment cycle. Thyroid antibody levels were measured prior to
entry into the study, and subsequently on alternate treatment
cycles (i.e. at monthly intervals) while on treatment.
Statistical analysis
Differences in survival between groups were analysed using a
log-rank test. Further statistical analysis of these data was
complicated by the fact that patients failing to respond to
treatment were withdrawn after two treatment cycles, while
those patients responded to treatment continued on study. In
order to determine whether abnormal thyroid function was a
predictor of survival, while allowing for the longer treatment
period in responding patients, we used a time-dependent Cox
model to analyse these data.
Results
Seventeen patients have been treated according to this pro-
tocol. One patient had a history of previous thyroidectomy
and was found to be hypothyroid prior to commencing
treatment, and was excluded from further analysis. Three
patients received two treatment cycles or fewer. All three
were in progressive disease at the time of withdrawal from
the study, and all have since died of progressive disease.
Thyroid function tests on these three patients were normal
while on treatment. However, as thyroid dysfunction did not
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develop in most patients until the third treatment cycle or later, these three patients were also excluded from further
analysis. Thirteen patients were therefore evaluated for this study. The clinical characteristics are summarised in Table I. The median age of the group was 59 years (range 32-70 years). All patients had normal T4 and TSH levels at entry into the study, and no patient had anti-thyroid antibodies
detected. None of the patients had a previous history of thyroid disease or thyroid surgery.
The 13 patients received a total of 104 treatment cycles (median seven cycles; range 3-15 cycles). Six patients (46%) developed biochemical thyroid dysfunction during treatment (defined as T4 or TSH levels outside the normal range ofour laboratory on two consecutive treatment cycles). The remain- ing seven patients (54%) had no abnormalities of thyroid function detected. None of the 13 patients had anti-thyroid
antibodies detected at any time during their course of treat-
ment.
There was no correlation between age, sex, type of malig- nancy or Karnofsky Index and the development of thyroid dysfunction. The pattern of thyroid dysfunction which devel- oped during treatment with IL-2 and IFN20c was similar in all six patients (Figure 1). Four patients developed elevated T4 with sub-normal TSH levels during the second to fifth treatment cycles. Three of these patients then became hypo- thyroid between the sixth and ninth cycles, and were com- menced on replacement treatment with thyroxine. The fourth
patient had an initial transient rise in T4, but subsequently maintained a normal T4 level with markedly elevated TSH (8 to 28: normal range 0.5-5). A fifth patient had a initial fall in TSH on the fourth and fifth cycles without a rise in T4. He subsequently became hypothyroid on the ninth cycle and was commenced on thyroxine. The last patient deviated
slightly from this pattern in that his thyroid function
remained normal up to cycle eight. He then developed raised
T4 with low TSH levels. This patient is still on treatment. Altogether, four patients required replacement therapy with thyroxine. Two patients had abnormalities of thyroid function, but did not become hypothyroid.
Tumour response
Five patients had progressive disease with no response to
treatment and were therefore withdrawn from the study after
two months (four treatment cycles). All of these patients have since died of progressive disease.
One patient had stable disease and continued on treatment for a total for 5 months (13 treatment cycles). She then developed refractory hypotension associated with IL-2 infu- sion, and was withdrawn from further treatment. A second patient was assessed as having stable disease after four treat- ment cycles, but was withdrawn from the treatment protocol at her own request. Both these patients have since died of progressive disease.
Two patients with stable disease at 6 months (12 cycles)
Table I Patient characteristics
Site of Patient Age Sex KI Primary disease metastases
1 32 F 80 Melanoma Multiple 2 44 M 90 Renal Pulmonary 3 55 F 90 Melanoma Cutaneous 4 65 M 90 Renal Lymphadenopathy 5 58 M 90 Renal Pulmonary 6 45 M 90 Renal Multiple 7 48 F 80 Renal Multiple 8 70 F 80 Renal Multiple 9 64 F 80 Renal Multiple 10 62 F 70 Melanoma Intra-abdominal 11 59 F 90 Melanoma Multiple 12 66 M 70 Melanoma Multiple 13 63 M 80 Renal Multiple
KI = Karnofsky Index at entry. Multiple = Recurrent disease affecting more than one body system.
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Figure 1 T4/TSH levels during IL2 and IFN-2a therapy.
were withdrawn from treatment at that point. One of these patients is now disease-free after surgical resection ofresidual disease. The second patient has since developed progressive disease. One patient had an initial partial response, but relapsed while on treatment and was withdrawn at 6 months (12 cycles).
Three patients achieved a partial response after 6 months
on treatment. One of these has since developed progressive disease, but the two partial responses remain. Of the 13 patients, four partial responses were observed (30.8%), with four patients (30.8%) achieving stable disease while on treat-
ment. Five patients (38.5%) had progressive disease with no
response to treatment. There were no complete responses.
Correlation between thyroidfunction and tumour response (Table II)
Of the six patients with abnormalities ofthyroid function, all had either stable disease or a partial response. Seven patients had normal thyroid function throughout their treatment, two (29%) experiencing stable disease while
on treatment.
Survival andthyroidfunction
Of six patients who developed thyroid dysfunction while on treatment, five patients (83%) were alive at the time of writing. The median survival in this group to date is 13.5 months (range 8-20 months) (Figure 2). All those who maintained normal thyroid indices have died between 1.5 and 7 months after starting therapy. The median survival of this group is 3 months (range 1.5-7 months).
Table II Thyroid dysfunction and outcome
Current Thyroid Duration of Patient Response status function Cycle* treatment
I SD ALIVE ABN 4 14 2 PR/PD DEAD ABN 3 6 3 PR ALIVE ABN 2 13 4 SD/PD ALIVE ABN 4 13
5 PR ALIVE ABN 3 9 6 PR ALIVE ABN 8 13 7 SD DEAD N / 8 8 SD DEAD N / 4 9 PD DEAD N / 2 10 PD DEAD N / 4 11 PD DEAD N / 4 12 PD DEAD N / 3 13 PD DEAD N / 4
PR partial response; SD= stable disease; PD=progressive disease; PR/PD = initial partial response followed by progressive disease; ABN =abnormal; N = normal. *Refers to cycle at which thyroid dysfunction was first noted. Duration oftreatment in cycles.IMMUNOTHERAPY AND THYROID FUNCTION 917
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Figure 2 Overall survival.
Using a log-rank test, the difference in survival between these
two groups is significant with P = 0.049. However, using a
time dependent Cox model to determine whether the develop-
ment of thyroid dysfunction was a positive predictor of
survival, the difference between the groups was not signi-
ficant (P = 0.7075), i.e. there was no significant correlation
between survival and the development of thyroid dysfunc-
tion.
Discussion
The development of abnormal thyroid function has been well
documented in association with treatment with alpha-inter-
feron alone, IL-2 alone, IL-2 plus LAK cells, and IL-2 plus
alpha-interferon (Atkins et al., 1988; Pichert et al., 1990).
The mechanism responsible for this phenomenon has not
been fully elucidated, but it is probably an auto-immune
phenomenon due to the induction of HLA class II antigens
on thyroid epithelial tissue (Atkins et al., 1988; Pichert et al.,
1990). The aim of this study was to examine the possible
correlation between the development of abnormal thyroid
function and tumour response in a group of patients receiv-
ing IL-2 and IFN-2a for advanced malignancy.
In this prospective study of 17 patients serum T4 and TSH
levels were measured every 2 weeks while on treatment. It is
unlikely that transient abnormalities of thyroid function were
missed in any patient. All patients had normal thyroid func-
tion prior to entry into the study.
Six of 13 patients developed some abnormality of thyroid
function during treatment, and it was particularly striking
that the pattern of thyroid abnormality which developed was
similar in all these patients. This pattern has been previously
noted (Pichert et al., 1990) in a study using the same protocol
of therapy and correlates well with an auto-immune pattern.
It is therefore of interest that none of these patients had
anti-thyroid antibodies detected. The other seven patients
had no abnormalities of thyroid function detected.
When survival is related to thyroid function, there is an
obvious correlation between the development of abnormal
thyroid function and longer survival. The median survival of
those patients developing thyroid dysfunction was more than
four times that of patients with normal thyroid status. How-
ever, the statistical analysis of this data is complicated by the
longer time on treatment of responding patients. The point at
issue is whether the development of abnormal thyroid func-
tion which occurred in these patients was due simply to
treatment with IL2 and IFN-2a, or whether it truly predicts a
tumour response to treatment. In five out of six patients
abnormal thyroid function developed early in the course of
treatment, between the second and fourth treatment cycles,
and did not require long-term treatment with IL2 and IFN-
2a (Table II). This would support the contention that abnor-
mal thyroid function is a predictor of disease response, rather
than a consequence of long-term treatment.
To allow for the fact that responding patients received a
longer course of treatment than non-responder, we used a
time-dependent Cox model for statistical analysis. Using this
model in this small group of patients we were unable to
confirm statistically that abnormal thyroid function was a
predictor of disease response.
Other studies have reported abnormal thyroid function in
patients treated with IFN-2a alone. Burman et al. (1986)
noted thyroid dysfunction in seven out of 39 patients receiv-
ing human leukocyte-derived alpha-interferon (huLe-IFN)
for carcinoid tumours. Fentiman et al. (1988) reported the
development of hypothyroidism in three out of ten patients
treated with huLe-IFN for locoregional recurrence of breast
carcinoma. However, thyroid dysfunction has not been assoc-
iated with recombinant IFN-2a used alone, and it has been
suggested that thyroid dysfunction with huLe-IFN is due to
the presence of small amounts of gamma-interferon in the
huLe-IFN preparation (Burman et al., 1986).
It is not clear why immunotherapy with IL-2 and IFN-2a
should induce auto-immune thyroiditis but not other forms
of auto-immune disease. A crucial step in the initiation of an
immune response is the recognition by antigen-specific T-cells
of MHC class II molecules on the surface ofantigen present-
ing cells. Normal thyroid cells do not express MHC class II
antigens; in contrast, thyrocytes from patients with auto-
immune thyroid disease have been shown to do so (Hanafusa
et al., 1983). HLA class II expression can be induced on
cultured thyroid cells by the addition ofIFN-gamma, but not
by adding IFN-alpha or IL-2 without IFN-gamma (Todd et
al., 1985). One action of IL-2 however is to induce IFN-
gamma production by T-lymphocytes, and possibly also by
NK cells (Kasahara et al., 1983). Development of auto-
immune thyroiditis after IL-2 therapy may therefore be due
to IFN-gamma production from activated T-lymphocytes,
which results in MHC class II antigen expression on thyroid
tissue.
Cohen et al. (1987) have reported a correlation between
HLA-DR expression on tumour cells and response to ther-
apy with IL-2 plus LAK. It therefore appears that response
to therapy with IL-2 may correlate with the expression of
HLA class II antigens on both tumour cells and thyroid
tissue. However, whereas Cohen et al. reported that four out
of five responding tumours were HLA-DR positive before
therapy, none of our patient had evidence ofthyroiditis until
after commencing IL-2 therapy.
Pichert et al. (1990) performed fine needle aspiration cyto-
logy (FNAC) in three patients who developed thyroid dys-
function while undergoing treatment with IL-2 and IFN. All
three patients were reported as having evidence of chronic
thyroiditis, and all three had strong expression of HLA-DR
antigen on thyroid tissue. We did not obtain FNAC on our
series of patients, but in future it would be of interest to
perform thyroid FNAC prior to starting treatment and again
after the appearance of thyroid dysfunction. It may be that
the presence of HLA-DR antigen on thyroid tissue will
predict response to therapy.
It is clear from this study that patients undergoing treat-
ment with IL-2 and IFN are at a high risk of developing
thyroid dysfunction. Such patients should have regular
assessment of thyroid function, and may require replacement
therapy with thyroxine. However, as not all patients become
hypothyroid, and as some patients may pass through an
initial transient episode of hyperthyroidism before becoming
hypothyroid, prophylactic therapy with thyroxine for all
patients receiving IL-2 and IFN is not recommended.
Thyroid dysfunction is a common side-effect of therapy
with IL2 plus IFN-alpha. In this small group, patients who
developed abnormal thyroid function while on treatment
with IL2 and IFN-2a had longer survival and were more
likely to respond to treatment than patients without thyroid
dysfunction, although in such a small number ofpatients we
have been unable to definitively correlate abnormal thyroid
function with tumour response.
The development ofthyroid dysfunction may be associated
with tumour response to treatment. The mechanisms of this
response, and the usefulness of HLA-DR expression on
tumour or thyroid tissue as a predictor of response to
therapy requires further evaluation.
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